0001628280-20-004260.txt : 20200327
0001628280-20-004260.hdr.sgml : 20200327
20200327210341
ACCESSION NUMBER: 0001628280-20-004260
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200101
FILED AS OF DATE: 20200327
DATE AS OF CHANGE: 20200327
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: REICHLING STEVEN
CENTRAL INDEX KEY: 0001556290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31822
FILM NUMBER: 20753641
MAIL ADDRESS:
STREET 1: 7000 NORTH BROADWAY, BUILDING 3-307
CITY: DENVER
STATE: CO
ZIP: 80221
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Accelerate Diagnostics, Inc
CENTRAL INDEX KEY: 0000727207
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 841072256
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3950 S. COUNTRY CLUB ROAD #470
STREET 2: BUILDING 3-307
CITY: TUCSON
STATE: AZ
ZIP: 85714
BUSINESS PHONE: 303-863-8088
MAIL ADDRESS:
STREET 1: 3950 S. COUNTRY CLUB ROAD #470
STREET 2: BUILDING 3-307
CITY: TUCSON
STATE: AZ
ZIP: 85714
FORMER COMPANY:
FORMER CONFORMED NAME: ACCELR8 TECHNOLOGY CORP
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: HYDRO SEEK INC
DATE OF NAME CHANGE: 19880802
4
1
wf-form4_158535740296011.xml
FORM 4
X0306
4
2020-01-01
0
0000727207
Accelerate Diagnostics, Inc
AXDX
0001556290
REICHLING STEVEN
C/O ACCELERATE DIAGNOSTICS, INC.
3950 S. COUNTRY CLUB ROAD, SUITE 470
TUCSON
AZ
85714
0
1
0
0
Chief Financial Officer
Employee Stock Option (right to buy)
16.9
2020-01-01
4
A
0
12634
3.96
A
2030-01-01
Common Stock
12634.0
12634
D
This Form 4 was inadvertently not filed within the required time following the transaction date of January 1, 2020.
Option awards vest in equal monthly amounts over twelve months, with the first installment vesting on January 31, 2020.
The options were issued to the reporting person under the 2020 Salary Waiver and Nonqualified Stock Option Grant Plan (the "Sub-Plan") established pursuant to the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan. Pursuant to the terms of the Sub-Plan, the reporting person irrevocably waived $50,000 of base compensation scheduled to be paid to the reporting person in 2020 in exchange for such options.
/s/ Steve Reichling
2020-03-27